Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Impaired fasting glucose is associated with unfavorable outcome in ischemic stroke patients treated with intravenous alteplase

Impaired fasting glucose is associated with unfavorable outcome in ischemic stroke patients... Objectives Hyperglycemia on admission and diabetes mellitus type II are associated with unfavorable outcome in stroke patients. We studied whether impaired fasting glucose (IFG) is associated with unfavorable outcome in ischemic stroke patients treated with intravenous alteplase as well and if IFG is a stronger prognostic factor than hyperglycemiaon admission. Methods We studied 220 consecutive patients with ischemic stroke treated with intravenous alteplase. In all nondiabetic patients, fasting glucose was determined on day 2–5. IFG was defined as fasting glucose level of ≥ 5.6 mmol/L, hyperglycemia on admission as glucose levels ≥ 7.9 mmol/L. The primary effect measure was the adjusted common odds ratio (acOR) for a shift in the direction of worse outcome on the modified Rankin Scale at 3 months, estimated with ordinal logistic regression, and adjusted for common prognostic factors. Results The fasting glucose levels were available in 194 and admission glucose levels in 215 patients. Sixty-three (32.5%) had IFG, 58 (27%) hyperglycemia on admission and 32 (14.6%) pre-existent diabetes. Patients with IFG showed a shift towards worse functional outcome compared with patients with normal fasting glucose levels (acOR 2.77; 95% CI 1.54–4.97), which was stronger than hyperglycemia on admission (acOR 1.75; 95% CI 0.91–3.4). Conclusions IFG is associated http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Neurology Springer Journals

Impaired fasting glucose is associated with unfavorable outcome in ischemic stroke patients treated with intravenous alteplase

Download PDF
6 pages

Loading next page...
 
/lp/springer_journal/impaired-fasting-glucose-is-associated-with-unfavorable-outcome-in-gOiQitl4KS
Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer-Verlag GmbH Germany, part of Springer Nature
Subject
Medicine & Public Health; Neurology; Neurosciences; Neuroradiology
ISSN
0340-5354
eISSN
1432-1459
DOI
10.1007/s00415-018-8866-z
pmid
29666986
Publisher site
See Article on Publisher Site

Abstract

Objectives Hyperglycemia on admission and diabetes mellitus type II are associated with unfavorable outcome in stroke patients. We studied whether impaired fasting glucose (IFG) is associated with unfavorable outcome in ischemic stroke patients treated with intravenous alteplase as well and if IFG is a stronger prognostic factor than hyperglycemiaon admission. Methods We studied 220 consecutive patients with ischemic stroke treated with intravenous alteplase. In all nondiabetic patients, fasting glucose was determined on day 2–5. IFG was defined as fasting glucose level of ≥ 5.6 mmol/L, hyperglycemia on admission as glucose levels ≥ 7.9 mmol/L. The primary effect measure was the adjusted common odds ratio (acOR) for a shift in the direction of worse outcome on the modified Rankin Scale at 3 months, estimated with ordinal logistic regression, and adjusted for common prognostic factors. Results The fasting glucose levels were available in 194 and admission glucose levels in 215 patients. Sixty-three (32.5%) had IFG, 58 (27%) hyperglycemia on admission and 32 (14.6%) pre-existent diabetes. Patients with IFG showed a shift towards worse functional outcome compared with patients with normal fasting glucose levels (acOR 2.77; 95% CI 1.54–4.97), which was stronger than hyperglycemia on admission (acOR 1.75; 95% CI 0.91–3.4). Conclusions IFG is associated

Journal

Journal of Neurology – Springer Journals

Published: Apr 17, 2018

References

  • Association of admission blood glucose and outcome in patients treated with intravenous thrombolysis: results from the Safe Implementation of Treatments in Stroke International Stroke Thrombolysis Register (SITS-ISTR)
    Ahmed, N; Dávalos, A; Eriksson, N; Ford, GA; Glahn, J; Hennerici, M; Mikulik, R; Kaste, M; Lees, KR; Lindsberg, PJ; Toni, D
  • Effects of admission hyperglycemia on stroke outcome in reperfused tissue plasminogen activator–treated patients
    Alvarez-Sabín, J; Molina, CA; Montaner, J; Arenillas, JF; Huertas, R; Ribo, M; Codina, A; Quintana, M
  • Admission glucose level and clinical outcomes in the NINDS rt-PA Stroke Trial
    Bruno, A; Levine, SR; Frankel, MR; Brott, TG; Lin, Y; Tilley, BC; Lyden, PD; Broderick, JP; Kwiatkowski, TG; Fineberg, SE
  • Baseline serum glucose concentration and symptomatic haemorrhagic transformation in non-diabetic stroke patients treated by intravenous thrombolysis
    Gnofam, M; Leys, D; Ponchelle-Dequatre, N; Bodenant, M; Hénon, H; Bordet, R; Cordonnier, C
  • Acute hyperglycemia state is associated with lower tPA-induced recanalization rates in stroke patients
    Ribo, M; Molina, C; Montaner, J; Rubiera, M; Delgado-Mederos, R; Arenillas, JF; Quintana, M; Alvarez-Sabín, J
  • Glycosylated hemoglobin A1 predicts risk for symptomatic hemorrhage after thrombolysis for acute stroke
    Rocco, A; Heuschmann, PU; Schellinger, PD; Kohrmann, M; Diedler, J; Sykora, M; Nolte, CH; Ringleb, P; Hacke, W; Juttler, E
  • Diabetes mellitus, admission glucose, and outcomes after stroke thrombolysis: a registry and systematic review
    Desilles, JP; Meseguer, E; Labreuche, J; Lapergue, B; Sirimarco, G; Gonzalez-Valcarcel, J; Lavallée, P; Cabrejo, L; Guidoux, C; Klein, I; Amarenco, P; Mazighi, M
  • Baseline diabetic status and admission blood glucose were poor prognostic factors in the EPITHET trial
    Silva, DA; Ebinger, M; Christensen, S; Parsons, MW; Levi, C; Butcher, K; Barber, PA; Bladin, C; Donnan, GA; Davis, SM
  • The effect of metabolic syndrome and obesity on outcomes of acute ischemic stroke patients treated with systemic thrombolysis
    Bas, DF; Ozdemir, AO
  • Recanalization after thrombolysis in stroke patients: predictors and prognostic implications
    Zangerle, A; Kiechl, S; Spiegel, M; Furtner, M; Knoflach, M; Werner, P; Mair, A; Wille, G; Schmidauer, C; Gautsch, K; Gotwald, T; Felber, S; Poewe, W; Willeit, J
  • Prevalence of prediabetes and newly diagnosed diabetes in patients with a transient ischaemic attack or stroke
    Fonville, S; Zandbergen, AA; Vermeer, SE; Dippel, DW; Koudstaal, PJ; Hertog, HM
  • Fasting and 2-hour postchallenge serum glucose measures and risk of incident cardiovascular events in the elderly: the cardiovascular health study
    Smith, NL; Barzilay, JI; Shaffer, D; Savage, PJ; Heckbert, SR; Kuller, LH; Kronmal, RA; Resnick, HE; Psaty, BM
  • Fasting plasma glucose and risk of incident ischemic stroke or transient ischemic attacks: a prospective cohort study
    Tanne, D; Koren-Morag, N; Goldbourt, U
  • Standards of medical care in diabetes 2014
  • Higher fasting glucose next day after intravenous thrombolysis is independently associated with poor outcome in acute ischemic stroke
    Cao, W; Ling, Y; Wu, F; Yang, L; Cheng, X; Dong, Q
  • Acute hyperglycemia and acute hyperinsulinemia decrease plasma fibrinolytic activity and increase plasminogen activator inhibitor type 1 in the rat
    Pandolfi, A; Giaccari, A; Cilli, C; Alberta, MM; Morviducci, L; Filippis, EA; Buongiorno, A; Pellegrini, G; Capani, F; Consoli, A
  • Hyperglycemia and the vascular effects of cerebral ischemia
    Kawai, N; Keep, RF; Benz, AL
  • Moderate hyperglycemia worsens acute blood-brain barrier injury after forebrain ischemia in rats
    Dietrich, WD; Alonso, O; Busto, R
  • Classification of subtype of acute ischaemic stroke. Definitions for use in a multicenter clinical trial TOAST Trial of Org 10172 in Acute Stroke Treatment
    Adams, HP; Bendixen, BH; Kappelle, LJ; Biller, J; Love, BB; Gordon, DL; Marsh, EE
  • Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists
    Adams, HP; Zoppo, G; Alberts, MJ; Bhatt, DL; Brass, L; Furlan, A; Grubb, RL; Higashida, RT; Jauch, EC; Kidwell, C; Lyden, PD; Morgenstern, LB; Qureshi, AI; Rosenwasser, RH; Scott, PA; Wijdicks, EF
  • Ten year risk of cardiovascular incidence related to diabetes, prediabetes, and the metabolic syndrome
    Liu, J; Grundy, SM; Wang, W; Smith, SC; Vega, GL; Wu, Z; Zeng, Z; Wang, W; Zhao, D
  • Abnormal glucose metabolism in non-diabetic patients presenting with an acute stroke: prospective study and systematic review
    Dave, JA; Engel, ME; Freercks, R; Peter, J
  • Response of blood pressure and blood glucose to treatment with recombinant tissue-type plasminogen activator in acute ischemic stroke: evidence from the virtual international stroke trials archive
    Kerr, DM; Fulton, RL; Higgins, P; Bath, PM; Shuaib, A; Lyden, P; Lees, KR
  • Intravenous insulin therapy in the maintenance of strict glycemic control in nondiabetic acute stroke patients with mild hyperglycemia
    Staszewski, J; Brodacki, B; Kotowicz, J; Stepien, A
  • Glucose-potassium-insulin infusions in the management of post-stroke hyperglycaemia: the UK Glucose Insulin in Stroke Trial (GIST-UK)
    Gray, CS; Hildreth, AJ; Sandercock, PA; O’Connell, JE; Johnston, DE; Cartlidge, NE; Bamford, JM; James, OF; Alberti, K
  • Randomized, controlled trial of insulin for acute poststroke hyperglycemia
    McCormick, M; Hadley, D; McLean, JR; Macfarlane, JA; Condon, B; Muir, KW
  • Intensive versus subcutaneous insulin in patients with hyperacute stroke: results from the randomized INSULINFARCT trial
    Rosso, C; Corvol, JC; Pires, C; Crozier, S; Attal, Y; Jacqueminet, S; Deltour, S; Multlu, G; Leger, A; Meresse, I; Payan, C; Dormont, D; Samson, Y